|
所属 |
医学部 附属病院 コミュニティ・メディカルセンター |
|
職名 |
助教 |
|
関連SDGs |
|
論文 【 表示 ／ 非表示 】
-
Association between personality traits and glycemic control after inpatient diabetes education 査読あり
上野 浩晶, 清水 浩一郎, 山口 秀樹, Shimoda Kazuya, 内田 泰介, 小永田 綾香, 谷口 宗典, 鍋倉 弘樹, 古郷 芙未子, 長友 雄麻
Metabolism Open 18 100244 2023年6月
-
鍋倉 弘樹, イスラム エムディ ヌルル, 迫田 秀之, 張 維東, 中里 雅光
Obesity Facts 16 ( 4 ) 392 - 400 2023年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：S. Karger AG
Introduction: Vertical sleeve gastrectomy (VSG) is considered one of the most effective treatments for sustained weight loss and complete remission of type 2 diabetes mellitus (CR-T2DM). Liver-expressed antimicrobial peptide 2 (LEAP2), a ghrelin receptor antagonist peptide, is a metabolic hormone regulated by VSG. However, it is unknown whether LEAP2 can be used to predict the outcomes of VSG. This study aimed to evaluate LEAP2 as a predictive factor for weight loss and CR-T2DM after VSG.
Methods: This retrospective study included 39 Japanese participants with obesity who underwent VSG. Serum LEAP2, des-acyl ghrelin (DAG), and other metabolic and anthropometric parameters were studied before and at 12 months after VSG. Receiver operating characteristics (ROC) curve was generated to evaluate predictive score for weight loss with cut-off value of >50 percent excess weight loss. ROC curve was also generated to assess CR-T2DM.
Results: Serum LEAP2 levels were significantly higher in participants with body mass index (BMI) 32–50 kg/m2 than in those with normal weight. Participants with BMI >50 kg/m2 had lower serum LEAP2 concentrations than those with BMI 32–50 kg/m2. VSG caused a significant reduction in serum DAG concentrations, but it did not affect serum LEAP2 concentrations in either male or female participants. Preoperative serum LEAP2 concentration of 2.88 pmol/mL was the optimal cutoff value for predicting weight loss after VSG, with sensitivity of 80.0% and specificity of 75.9%. Preoperative serum LEAP2 level higher than 4.67 pmol/mL predicted CR-T2DM after VSG with sensitivity of 100% and specificity of 58.8%.
Conclusion: Preoperative serum LEAP2 could predict weight loss and CR-T2DM as outcomes of VSG. -
酒井 克也, 塩見 一剛, イスラム エムディ ヌルル, 鍋倉 弘樹, 迫田 秀之, 中里 雅光
Brain and Behavior 11 ( 5 ) 2021年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Wiley
Objective: To study the presence of liver-expressed antimicrobial peptide 2 (LEAP2) in human cerebrospinal fluid (CSF) and to measure its concentrations in neurologicaldisorders.
Materials & Methods: We identified the presence of LEAP2 in human CSF by chro-matographic analysis and a LEAP2-specific enzyme immunoassay. We measured LEAP2 concentrations in the CSF of 35 patients with neurological disorders.
Results: CSF LEAP2 concentrations in the bacterial meningitis group (mean ±SD, 9. 32± 3.76 ng/ml) were significantly higher (p< .05) than those in the other four groups (psychosomatic disorder, 0.56± 0.15 ng/ml; peripheral autoimmune dis-ease, 1.00 ± 0.60 ng/ml; multiple sclerosis, 0.62± 0.30 ng/ml; aseptic meningitis, 1.59± 0.69 ng/ml).
Conclusions: This is the first study to identify the presence of human LEAP2 in the CSF. Levels of LEAP2 were increased in the CSF of patients with bacterial meningitis. LEAP2 may have potential as a biomarker for bacterial meningitis.DOI： 10.1002/brb3.2111